Drug Profile

Arsenic trioxide - Teva Pharmaceutical Industries

Alternative Names: NSC-706363; Trisenox

Latest Information Update: 28 Jun 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CTI BioPharma
Developer Leukemia SPORE; Northwestern University; Temple University; Teva Pharmaceutical Industries; University of Texas M. D. Anderson Cancer Center
Class Anti-inflammatories; Antineoplastics; Arsenicals; Ischaemic heart disorder therapies; Oxides; Skin disorder therapies; Small molecules
Mechanism of Action Apoptosis stimulants; DNA synthesis inhibitors; Endothelial cell modulators; Immunostimulants; Thioredoxin reductase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Multiple myeloma; Myelodysplastic syndromes; Acute myeloid leukaemia; Acute promyelocytic leukaemia; Liver cancer; Chronic myeloid leukaemia; Glioma
New Molecular Entity Yes

Marketed Acute promyelocytic leukaemia
Phase II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
Phase I/II Glioma
Discontinued Multiple myeloma

26 Jun 2023 CTI BioPharma has been acquired by Swedish Orphan Biovitrum
05 Oct 2020 CTI Biopharma terminates a phase II trial for Myelodysplastic Syndromes in USA (IV) (NCT00020969)
06 Aug 2018 National Institutes of Health and Teva Pharmaceuticals terminates a phase I trial for Chronic myeloid leukaemia (second-line therapy or greater, combination thereapy) in USA (NCT01397734)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com